CLINICAL RESEARCH MANAGEMENT OFFICE The Clinical Research Management Office (CRMO) is the shared resource ofthe Kimmel Cancer Center (KCC) that supports physicians, scientists and other staff in the development, implementation, and conduct of clinical trials. The CRMO provides a broad range of services tailored to the specific needs of investigators, the KCC, and consortium partners. These services include supervision of activities related to trial registration and conduct, quality assurance, and monitoring of KCC institutional, pharmaceutical and cooperative group clinical trials. The CRMO also serves as a resource for the KCC community and patients by providing relevant information regarding clinical trial availability.
Specific aims of the CRMO include: Orientation of new faculty to KCC, CRMO and (TJU) policies and procedures related to clinical research cilitate the development of KCC investigator initiated clinical trials Coordinate the preparation and submission of studies for review by the Multidisciplinary Groups (MDG), Clinical Cancer Research Review Committee (CCRRC) and the Thomas Jefferson University Institutional Review Board (IRB) Collect, abstract, maintain and update data specific to patients entered on clinical trials Coordination of study visits and procedures related to clinical trials Assure timely and accurate preparation and submission of all regulatory reviews (e.g. new submissions, amendments, annual reports, safety information, etc. to the IRB and FDA) Serve as a liaison between the TJU IRB, FDA or other regulatory bodies, and KCC investigators Assure accurate entry of patients participating in KCC clinical trials in a centralized database Assist in the maintenance of an accurate shared drive repository for complete protocols and informed consents. To improve easy access to viewing clinical trials Participate in the integration and activation of OnCore clinical trials management system Assure appropriate integration of consortium partners into the conduct of clinical research

Public Health Relevance

The Clinical Research Management Office is a shared resource for the Kimmel Cancer Center that provides central management and oversight functions for cancer clinical trials of Thomas Jefferson University

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-15
Application #
8753672
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299
Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603

Showing the most recent 10 out of 807 publications